Resource Center
FOR PHARMCEUTICAL MANUFACTURERS
CMS Enforcement for ASP in Medicare Part B
CMS Enforcement of Average Sales Price (ASP) Submissions for all Medicare Part B Eligible Pharmaceuticals and BiopharmaceuticalsRecently, CMS has been sending letters to pharma and biopharma manufacturers (with and without MDRP agreements) indicating that they believe...
Top 3 Reasons Your AMP Changed
Top 3 Reasons Your AMP ChangedLarge variances in Average Manufacturer Price (AMP) values are a common source of inquiry for pharmaceutical manufacturers. Questions often arise when internal stakeholders are trying to understand an undesired rebate liability or a...
Continued Emergence of Drug Price Disclosure Legislation – April 2020
Continued Emergence of Drug Price Disclosure LegislationTips for staying compliant with an accelerating trendStates Have Gotten Aggressive with Fines Against Pharma Companies for Price Reporting Noncompliance This paper, our third in a series that looks at the rising...
Reasons Brand Drug Manufacturers Must Prepare For Final Rule Changes
2023 Final Rule Updates for Drug Manufacturers Originally published March 2022; updated May 2022UPDATE May 18, 2022 2023 was shaping up to be a year of challenging decisions for manufacturers and restricted access to critical pharmaceuticals for patients. The 2023...
American Rescue Plan Act of 2021
American Rescue Plan Act of 2021: Medicaid Rebate Inflation Penalties Will Soon Know No BoundsOn March 11, 2021, President Joe Biden signed into law the American Rescue Plan Act of 2021 (ARP21), also known as the COVID-19 Relief Bill. Many pharmaceutical manufacturers...
Another Update on Drug Price Disclosure Legislation – Feb 2021
Another Update on Drug Price Disclosure LegislationMore tips for staying compliant with an accelerating trendStates Continue Their March Toward Prescription Drug Transparency Regulations. This paper, our fourth in a series that looks at the rising number of price...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Professor Jeremy’s
KEY TERMS
FOR PHARMA EXECUTIVES
Pharmaceutical professionals often face challenges with the industry’s language, acronyms, and key players. This glossary offers an overview of essential terms every executive should know.